Thus, the goal of the present study was to determine the extent to which long-term oral EGX358 treatment could promote memory formation and reduce the magnitude of a drug-induced hot flash in female APOE4- and APOE4+ mice using the APOE+/+/5xFAD+/− (EFAD) transgenic model of AD, which models late-onset APOE-related AD risk by combining five amyloid precursor protein and presenilin mutations found in early-onset AD families with expression of human APOE gene variants (Youmans et al., 2012; Tai et al., 2017). Here, APOE is linked to Alzheimer disease.